Related references
Note: Only part of the references are listed.Chimeric antigen receptor T cell therapy: 25 years in the making
Saar Gill et al.
BLOOD REVIEWS (2016)
Irradiation and Immunotherapy: From Concept to the Clinic
April K. S. Salama et al.
CANCER (2016)
Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives
Markus Moehler et al.
EUROPEAN JOURNAL OF CANCER (2016)
Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population
Genta Sawada et al.
GASTROENTEROLOGY (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Molecular mechanisms of ethanol-associated oro-esophageal squamous cell carcinoma
Yao Liu et al.
CANCER LETTERS (2015)
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
Juan J. Rojas et al.
CLINICAL CANCER RESEARCH (2015)
Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
Koji Kurose et al.
CLINICAL CANCER RESEARCH (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences
Kai Wang et al.
ONCOLOGIST (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Going viral: a review of replication-selective oncolytic adenoviruses
Christopher Larson et al.
ONCOTARGET (2015)
PD-1 Restrains Radiotherapy-Induced Abscopal Effect
Sean S. Park et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis
V. Bagnardi et al.
BRITISH JOURNAL OF CANCER (2015)
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins et al.
CLINICAL CANCER RESEARCH (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Clinical outcomes of synchronous head and neck and esophageal cancer
Jae Won Park et al.
RADIATION ONCOLOGY JOURNAL (2015)
The Effect of Radiation on the Immune Response to Cancers
Bonggoo Park et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity
Suzanne Ostrand-Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2014)
Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients
Hisae Iinuma et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET (2014)
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
Susan J. Dutton et al.
LANCET ONCOLOGY (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Genomic and molecular characterization of esophageal squamous cell carcinoma
De-Chen Lin et al.
NATURE GENETICS (2014)
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
Chad Tang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Going viral with cancer immunotherapy
Brian D. Lichty et al.
NATURE REVIEWS CANCER (2014)
Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
Shinichi Kageyama et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial
Thomas Crosby et al.
LANCET ONCOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy
Ken Kato et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen
Kazuhiro Kakimi et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer
K Muro et al.
ANNALS OF ONCOLOGY (2004)